leadership
Angion’s leadership team has extensive experience
in clinical research and development, business
development, and commercialization. Angion is
applying its deep scientific expertise to advance its
pipeline to address acute organ injuries and
fibrotic diseases.
OUR EXECUTIVE
MANAGEMENT TEAM
Jay Venkatesan, MD, MBA
President, Chief Executive Officer, and Chairman
Prior to Angion, Dr. Venkatesan served as President and Director of Alpine Immune Sciences (ALPN), which he co-founded as a Managing Partner of Alpine BioVentures. Previously, Dr. Venkatesan was the founder and portfolio manager of Ayer Capital, a global healthcare fund. Prior to that, he served as a director at Brookside Capital, part of Bain Capital, where he co-managed healthcare investments. He was also a consultant at McKinsey & Co. and a venture investor with Patricof & Co. Ventures (now Apax Partners). He received his M.D. from the University of Pennsylvania School of Medicine, his M.B.A. from the Wharton School of the University of Pennsylvania, and his B.A. from Williams College.
Jennifer Rhodes
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer, & Secretary
Jennifer Rhodes
Executive Vice President, Chief Business Officer, General Counsel, Chief Compliance Officer, & Secretary
Ms. Rhodes previously served as General Counsel, Chief Business Officer, Chief Compliance Officer and Corporate Secretary of Adamas Pharmaceuticals, Inc. between April 2016 and January 2020. Before Adamas, Ms. Rhodes served as General Counsel and Corporate Secretary for Medivation, Inc., where she also served as Chief Compliance Officer. Prior to Medivation, Ms. Rhodes was an Assistant General Counsel at Pfizer Inc., where she supported the US primary care business and its primary care medicines development group. Before Pfizer, Ms. Rhodes was a Senior Associate in the Regulatory Law and International Trade Practice at Weil, Gotshal & Manges, LLP. She also served as a law clerk for Chief Judge Gregory A. Carman on the United States Court of International Trade. Ms. Rhodes received a JD from Wake Forest University School of Law and a BA in economics from Tulane University.
Greg Curhan
Chief Financial Officer
Greg Curhan has over 35 years of operational, financial, capital markets, and strategic advisory experience in various sectors including investment banking and medical device/life sciences. Prior to joining Angion, Greg was CFO and SVP Corporate Development of Providence Medical Technology, a venture backed medical device manufacturer. Prior to that Greg was CEO of Clickworker USA, a US subsidiary of a venture backed German Crowdsourcing platform. He was EVP and CFO of MCF Corporation, the parent company of Merriman Curhan Ford, an investment bank he co-founded. He was also CFO of WorldRes, a venture backed web-based hotel reservation booking engine. In addition, Greg has worked for various investment banking firms including Merrill Lynch, Montgomery Securities, Volpe Brown Whelan and MLV. Greg earned a BA degree in Economics (summa cum Laude and Phi Beta Kappa) from Dartmouth College.